Literature DB >> 8924193

Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe.

E Seifritz1, P Baumann, M J Müller, O Annen, M Amey, U Hemmeter, M Hatzinger, F Chardon, E Holsboer-Trachsler.   

Abstract

Pharmacokinetic measurements, neuroendocrine responses, and side effects profiles of intravenous infusions of 20 mg citalopram over 30 minutes during the early afternoon have been studied. Eight healthy male volunteers were enrolled in a placebo- (saline) controlled, single-blind, cross-over protocol. Plasma concentrations of the parent compound showed a double exponential decay. Demethyl and didemethyl metabolites were not detectable, but low concentrations of the propionic acid derivative of citalopram were found. Determination of the citalopram enantiomers yielded a balanced S(+)/R(-) ratio of 0.9 to 1.2. The endocrine response to the drug was characterized by significant increases in plasma prolactin and cortisol. Except for one subject, who developed pronounced side effects, human growth hormone showed a surge following saline that was inhibited following citalopram. Rectal temperature and heart rate were not affected and tolerability was favorable. Because of citalopram's extremely high selectivity for the presynaptic 5-hydroxytryptamine nerve terminals, the present data suggest that it might be a promising tool for the investigation of serotonergic function in the human brain in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8924193     DOI: 10.1016/0893-133X(95)00117-V

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  26 in total

Review 1.  Effects of medications on cerebral blood flow in late-life depression.

Authors:  Mitchell S Nobler; Kristian R Olvet; Harold A Sackeim
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

2.  Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging.

Authors:  Sakthivel Sekar; M Verhoye; J Van Audekerke; G Vanhoutte; Andrew S Lowe; Andrew M Blamire; Thomas Steckler; A Van der Linden; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2010-11-20       Impact factor: 4.530

Review 3.  Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management.

Authors:  Flora Coker; David Taylor
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

4.  A placebo-controlled study of sertraline's effect on cortisol response to the dexamethasone/corticotropin-releasing hormone test in healthy adults.

Authors:  Linda L Carpenter; Audrey R Tyrka; Janet K Lee; Aaron P Tracy; Charles W Wilkinson; Lawrence H Price
Journal:  Psychopharmacology (Berl)       Date:  2011-05-27       Impact factor: 4.530

Review 5.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 6.  Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.

Authors:  G J H Dumont; S J de Visser; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

7.  Specific effects of escitalopram on neuroendocrine response.

Authors:  Emily R Hawken; James A Owen; Robert W Hudson; Nicholas J Delva
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

8.  Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography.

Authors:  Gwenn S Smith; Yilong Ma; Vijay Dhawan; Thomas Chaly; David Eidelberg
Journal:  Synapse       Date:  2009-01       Impact factor: 2.562

9.  Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers.

Authors:  Carmine M Pariante; Andrew S Papadopoulos; Lucia Poon; Anthony J Cleare; Stuart A Checkley; Judie English; Robert W Kerwin; Stafford Lightman
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

10.  The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks.

Authors:  A Rodenbeck; S Cohrs; W Jordan; G Huether; E Rüther; G Hajak
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.